Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study

DOI record: { "DOI": "10.1007/s40744-021-00373-1", "ISSN": [ "2198-6576", "2198-6584" ], "URL": "http://dx.doi.org/10.1007/s40744-021-00373-1", "alternative-id": [ "373" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "14 July 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "6 September 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "16 September 2021" } ], "author": [ { "affiliation": [], "family": "Guillaume", "given": "Debellemanière", "sequence": "first" }, { "affiliation": [], "family": "Magalie", "given": "Bouvet", "sequence": "additional" }, { "affiliation": [], "family": "Sina", "given": "Elahi", "sequence": "additional" }, { "affiliation": [], "family": "Imène", "given": "Salah-Mabed", "sequence": "additional" }, { "affiliation": [], "family": "Frédéric", "given": "Vayr", "sequence": "additional" }, { "affiliation": [], "family": "Mathieu", "given": "Dubois", "sequence": "additional" }, { "affiliation": [], "family": "Aurore", "given": "Muselier", "sequence": "additional" }, { "affiliation": [], "family": "Yoni", "given": "Gozlan", "sequence": "additional" }, { "affiliation": [], "family": "Emma", "given": "Elbaz", "sequence": "additional" }, { "affiliation": [], "family": "Charlotte", "given": "Badatcheff", "sequence": "additional" }, { "affiliation": [], "family": "Laura", "given": "Fabre", "sequence": "additional" }, { "affiliation": [], "family": "Alain", "given": "Saad", "sequence": "additional" }, { "affiliation": [], "family": "Steven", "given": "Nahaisi", "sequence": "additional" }, { "affiliation": [], "family": "Pierre", "given": "Zeboulon", "sequence": "additional" }, { "affiliation": [], "family": "Jean-Luc", "given": "Febbraro", "sequence": "additional" }, { "affiliation": [], "family": "Romain", "given": "Courtin", "sequence": "additional" }, { "affiliation": [], "family": "Alice", "given": "Grise-Dulac", "sequence": "additional" }, { "affiliation": [], "family": "Adrien", "given": "Mazharian", "sequence": "additional" }, { "affiliation": [], "family": "Wassim", "given": "Ghazal", "sequence": "additional" }, { "affiliation": [], "family": "Pierre-Emmanuel", "given": "Remongin", "sequence": "additional" }, { "affiliation": [], "family": "Christophe", "given": "Panthier", "sequence": "additional" }, { "affiliation": [], "family": "Catherine", "given": "Chirouze", "sequence": "additional" }, { "affiliation": [], "family": "Kevin", "given": "Bertrand", "sequence": "additional" }, { "affiliation": [], "family": "Thomas", "given": "Sené", "sequence": "additional" }, { "affiliation": [], "family": "Damien", "given": "Gatinel", "sequence": "additional" } ], "container-title": "Rheumatology and Therapy", "container-title-short": "Rheumatol Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 9, 16 ] ], "date-time": "2021-09-16T12:13:30Z", "timestamp": 1631794410000 }, "deposited": { "date-parts": [ [ 2021, 11, 6 ] ], "date-time": "2021-11-06T22:11:29Z", "timestamp": 1636236689000 }, "indexed": { "date-parts": [ [ 2023, 7, 1 ] ], "date-time": "2023-07-01T10:18:03Z", "timestamp": 1688206683656 }, "is-referenced-by-count": 4, "issue": "4", "issued": { "date-parts": [ [ 2021, 9, 16 ] ] }, "journal-issue": { "issue": "4", "published-print": { "date-parts": [ [ 2021, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 9, 16 ] ], "date-time": "2021-09-16T00:00:00Z", "timestamp": 1631750400000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 9, 16 ] ], "date-time": "2021-09-16T00:00:00Z", "timestamp": 1631750400000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s40744-021-00373-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s40744-021-00373-1/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s40744-021-00373-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "1887-1895", "prefix": "10.1007", "published": { "date-parts": [ [ 2021, 9, 16 ] ] }, "published-online": { "date-parts": [ [ 2021, 9, 16 ] ] }, "published-print": { "date-parts": [ [ 2021, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1038/s41421-020-0156-0", "author": "J Liu", "doi-asserted-by": "publisher", "first-page": "16", "issue": "1", "journal-title": "Cell Discov", "key": "373_CR1", "unstructured": "Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16.", "volume": "6", "year": "2020" }, { "DOI": "10.1093/cid/ciaa237", "author": "X Yao", "doi-asserted-by": "publisher", "first-page": "732", "issue": "15", "journal-title": "Clin Infect Dis", "key": "373_CR2", "unstructured": "Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–9.", "volume": "71", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.105949", "author": "P Gautret", "doi-asserted-by": "publisher", "first-page": "105949", "issue": "1", "journal-title": "Int J Antimicrob Agents", "key": "373_CR3", "unstructured": "Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.", "volume": "56", "year": "2020" }, { "DOI": "10.1016/j.tmaid.2020.101791", "author": "J-C Lagier", "doi-asserted-by": "publisher", "first-page": "101791", "journal-title": "Travel Med Infect Dis", "key": "373_CR4", "unstructured": "Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791.", "volume": "36", "year": "2020" }, { "DOI": "10.1002/jmv.26286", "author": "A Ferreira", "doi-asserted-by": "publisher", "first-page": "755", "issue": "2", "journal-title": "J Med Virol", "key": "373_CR5", "unstructured": "Ferreira A, Oliveira-E-Silva A, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol. 2021;93(2):755–9.", "volume": "93", "year": "2021" }, { "DOI": "10.1016/j.ijid.2021.04.035", "author": "RCS Seet", "doi-asserted-by": "publisher", "first-page": "314", "journal-title": "Int J Infect Dis", "key": "373_CR6", "unstructured": "Seet RCS, Quek AML, Ooi DSQ, Sengupta S, Lakshminarasappa SR, Koo CY, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial. Int J Infect Dis. 2021;106:314–22.", "volume": "106", "year": "2021" }, { "DOI": "10.1001/jama.2020.8630", "author": "ES Rosenberg", "doi-asserted-by": "publisher", "first-page": "2493", "issue": "24", "journal-title": "JAMA", "key": "373_CR7", "unstructured": "Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–502.", "volume": "323", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-217566", "author": "A Mathian", "doi-asserted-by": "publisher", "first-page": "837", "issue": "6", "journal-title": "Ann Rheum Dis", "key": "373_CR8", "unstructured": "Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837–9.", "volume": "79", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-217690", "author": "MF Konig", "doi-asserted-by": "publisher", "first-page": "1386", "issue": "10", "journal-title": "Ann Rheum Dis", "key": "373_CR9", "unstructured": "Konig MF, Kim AHJ, Scheetz MH, Graef ER, Liew JW, Simard J, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020;79(10):1386–8.", "volume": "79", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-218647", "author": "E Sbidian", "doi-asserted-by": "publisher", "journal-title": "Ann Rheum Dis", "key": "373_CR10", "unstructured": "Sbidian E, Penso L, Herlemont P, Botton J, Baricault B, Semenzato L, et al. Comment on “Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19” by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54,873 exposed individuals and 155,689 matched unexposed individuals in France. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-218647.", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-217871", "author": "M Gianfrancesco", "doi-asserted-by": "publisher", "first-page": "859", "issue": "7", "journal-title": "Ann Rheum Dis", "key": "373_CR11", "unstructured": "Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–66.", "volume": "79", "year": "2020" }, { "DOI": "10.1016/S2665-9913(20)30378-7", "author": "CT Rentsch", "doi-asserted-by": "publisher", "first-page": "e19", "issue": "1", "journal-title": "Lancet Rheumatol", "key": "373_CR12", "unstructured": "Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19-27.", "volume": "3", "year": "2021" }, { "DOI": "10.1056/NEJMoa2012410", "author": "J Geleris", "doi-asserted-by": "publisher", "first-page": "2411", "issue": "25", "journal-title": "N Engl J Med", "key": "373_CR13", "unstructured": "Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–8.", "volume": "382", "year": "2020" }, { "DOI": "10.1371/journal.pone.0251262", "author": "D Sammartino", "doi-asserted-by": "publisher", "first-page": "e0251262", "issue": "5", "journal-title": "PLoS ONE", "key": "373_CR14", "unstructured": "Sammartino D, Jafri F, Cook B, La L, Kim H, Cardasis J, et al. Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: a retrospective analysis. PLoS ONE. 2021;16(5):e0251262.", "volume": "16", "year": "2021" }, { "DOI": "10.1093/aje/kwab183", "author": "H Gerlovin", "doi-asserted-by": "publisher", "journal-title": "Am J Epidemiol", "key": "373_CR15", "unstructured": "Gerlovin H, Posner DC, Ho Y-L, Rentsch CT, Tate JP, King JT Jr, et al. Pharmacoepidemiology, machine learning and COVID-19: an intent-to-treat analysis of hydroxychloroquine, with or without azithromycin, and COVID-19 outcomes amongst hospitalized US Veterans. Am J Epidemiol. 2021. https://doi.org/10.1093/aje/kwab183.", "year": "2021" }, { "DOI": "10.1056/NEJMoa2019014", "author": "AB Cavalcanti", "doi-asserted-by": "publisher", "first-page": "2041", "issue": "21", "journal-title": "N Engl J Med", "key": "373_CR16", "unstructured": "Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041–52.", "volume": "383", "year": "2020" }, { "DOI": "10.9778/cmajo.20210069", "author": "I Schwartz", "doi-asserted-by": "publisher", "first-page": "E693", "issue": "2", "journal-title": "CMAJ Open", "key": "373_CR17", "unstructured": "Schwartz I, Boesen ME, Cerchiaro G, Doram C, Edwards BD, Ganesh A, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. CMAJ Open. 2021;9(2):E693-702.", "volume": "9", "year": "2021" }, { "DOI": "10.1183/13993003.00752-2021", "author": "P Sivapalan", "doi-asserted-by": "publisher", "journal-title": "Eur Respir J", "key": "373_CR18", "unstructured": "Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, Dahlin Bojesen R, Eklöf J, Browatzki A, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. Eur Respir J. 2021. https://doi.org/10.1183/13993003.00752-2021.", "year": "2021" }, { "DOI": "10.1016/j.cmi.2021.05.020", "author": "F Ader", "doi-asserted-by": "publisher", "journal-title": "Clin Microbiol Infect", "key": "373_CR19", "unstructured": "Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.05.020.", "year": "2021" }, { "DOI": "10.1038/s41598-021-88509-9", "author": "Á Réa-Neto", "doi-asserted-by": "publisher", "first-page": "9023", "issue": "1", "journal-title": "Sci Rep", "key": "373_CR20", "unstructured": "Réa-Neto Á, Bernardelli RS, Câmara BMD, Reese FB, Queiroga MVO, Oliveira MC. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 2021;11(1):9023.", "volume": "11", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2021.6468", "author": "G Reis", "doi-asserted-by": "publisher", "first-page": "e216468", "issue": "4", "journal-title": "JAMA Netw Open", "key": "373_CR21", "unstructured": "Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. 2021;4(4):e216468.", "volume": "4", "year": "2021" }, { "DOI": "10.1016/j.cmi.2021.03.005", "author": "V Dubée", "doi-asserted-by": "publisher", "journal-title": "Clin Microbiol Infect", "key": "373_CR22", "unstructured": "Dubée V, Roy P-M, Vielle B, Parot-Schinkel E, Blanchet O, Darsonval A, et al. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. Clin Microbiol Infect. 2019. https://doi.org/10.1016/j.cmi.2021.03.005.", "year": "2019" }, { "DOI": "10.1080/20477724.2021.1890887", "author": "LEB Galan", "doi-asserted-by": "publisher", "first-page": "235", "issue": "4", "journal-title": "Pathog Glob Health", "key": "373_CR23", "unstructured": "Galan LEB, Santos NMD, Asato MS, Araújo JV, de Lima MA, Araújo AMM, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathog Glob Health. 2021;115(4):235–42.", "volume": "115", "year": "2021" }, { "DOI": "10.1016/j.eclinm.2021.100773", "author": "C Johnston", "doi-asserted-by": "publisher", "first-page": "100773", "journal-title": "EClinicalMedicine", "key": "373_CR24", "unstructured": "Johnston C, Brown ER, Stewart J, Karita HCS, Kissinger PJ, Dwyer J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: a randomized clinical trial. EClinicalMedicine. 2021;33:100773.", "volume": "33", "year": "2021" }, { "DOI": "10.3390/jcm10122609", "author": "AV Hernandez", "doi-asserted-by": "publisher", "journal-title": "J Clin Med Res", "key": "373_CR25", "unstructured": "Hernandez AV, Ingemi J 3rd, Sherman M, Pasupuleti V, Barboza JJ, Piscoya A, et al. Impact of prophylactic hydroxychloroquine on people at high risk of COVID-19: a systematic review and meta-analysis. J Clin Med Res. 2021. https://doi.org/10.3390/jcm10122609.", "year": "2021" }, { "DOI": "10.3390/jcm10112503", "author": "AV Hernandez", "doi-asserted-by": "publisher", "journal-title": "J Clin Med Res", "key": "373_CR26", "unstructured": "Hernandez AV, Phan MT, Rocco J, Pasupuleti V, Barboza JJ, Piscoya A, et al. Efficacy and safety of hydroxychloroquine for hospitalized COVID-19 patients: a systematic review and meta-analysis. J Clin Med Res. 2021. https://doi.org/10.3390/jcm10112503.", "year": "2021" }, { "DOI": "10.1080/20477724.2021.1936818", "author": "A Di Castelnuovo", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Pathog Glob Health", "key": "373_CR27", "unstructured": "Di Castelnuovo A, Costanzo S, Cassone A, Cauda R, De Gaetano G, Iacoviello L. Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. Pathog Glob Health. 2021;15:1–11.", "volume": "15", "year": "2021" }, { "DOI": "10.1038/s41598-021-91089-3", "author": "B Amani", "doi-asserted-by": "publisher", "first-page": "11974", "issue": "1", "journal-title": "Sci Rep", "key": "373_CR28", "unstructured": "Amani B, Khanijahani A, Amani B. Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. Sci Rep. 2021;11(1):11974.", "volume": "11", "year": "2021" }, { "DOI": "10.1038/s41467-021-22446-z", "author": "C Axfors", "doi-asserted-by": "publisher", "first-page": "2349", "issue": "1", "journal-title": "Nat Commun", "key": "373_CR29", "unstructured": "Axfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349.", "volume": "12", "year": "2021" }, { "author": "P Eze", "first-page": "93", "issue": "1", "journal-title": "Am J Cardiovasc Dis", "key": "373_CR30", "unstructured": "Eze P, Mezue KN, Nduka CU, Obianyo I, Egbuche O. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Dis. 2021;11(1):93–107.", "volume": "11", "year": "2021" }, { "DOI": "10.1007/s10067-021-05779-4", "author": "B Yousefghahari", "doi-asserted-by": "publisher", "journal-title": "Clin Rheumatol", "key": "373_CR31", "unstructured": "Yousefghahari B, Navari S, Sadeghi M, Soleimaniamiri S, Soleimaniamiri M, Heidari B, et al. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2021. https://doi.org/10.1007/s10067-021-05779-4.", "year": "2021" }, { "DOI": "10.1093/rap/rkab014", "author": "K Pham", "doi-asserted-by": "publisher", "first-page": "rkab014", "issue": "1", "journal-title": "Rheumatol Adv Pract.", "key": "373_CR32", "unstructured": "Pham K, Torres H, Satlin MJ, Goyal P, Gulick RM. Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. Rheumatol Adv Pract. 2021;5(1):rkab014.", "volume": "5", "year": "2021" }, { "DOI": "10.1093/rheumatology/keaa897", "author": "R Cordtz", "doi-asserted-by": "publisher", "journal-title": "Rheumatology", "key": "373_CR33", "unstructured": "Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology. 2020. https://doi.org/10.1093/rheumatology/keaa897.", "year": "2020" }, { "DOI": "10.1371/journal.pone.0255343", "author": "JE Dalton", "doi-asserted-by": "publisher", "first-page": "e0255343", "issue": "8", "journal-title": "PLoS ONE", "key": "373_CR34", "unstructured": "Dalton JE, Gunzler DD, Jain V, Perzynski AT, Dawson NV, Einstadter D, Tarabichi Y, Imrey PB, Lewis M, Kattan MW, Yao J, Taksler G, Berg KA, Krieger NI, Kaelber D, Jehi L, Kalra A. Mechanisms of socioeconomic differences in COVID-19 screening and hospitalizations. PLoS ONE. 2021;16(8):e0255343.", "volume": "16", "year": "2021" }, { "DOI": "10.1111/irv.12901", "doi-asserted-by": "crossref", "key": "373_CR35", "unstructured": "Zerbo O, Lewis N, Fireman B, Goddard K, Skarbinski J, Sejvar JJ, Azziz-Baumgartner E, Klein NP. Population-based assessment of risks for severe COVID-19 disease outcomes. Influenza Other Respir Viruses. 2021." }, { "DOI": "10.1371/journal.pone.0255544", "author": "M Sandoval", "doi-asserted-by": "publisher", "first-page": "e0255544", "issue": "7", "journal-title": "PLoS ONE", "key": "373_CR36", "unstructured": "Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity of COVID-19 in hospital patients aged 18–29 years. PLoS ONE. 2021;16(7):e0255544.", "volume": "16", "year": "2021" }, { "DOI": "10.1371/journal.pone.0255171", "author": "Y Zhang", "doi-asserted-by": "publisher", "first-page": "e0255171", "issue": "7", "journal-title": "PLoS ONE", "key": "373_CR37", "unstructured": "Zhang Y, Khullar D, Wang F, Steel P, Wu Y, Orlander D, Weiner M, Kaushal R. Socioeconomic variation in characteristics, outcomes, and healthcare utilization of COVID-19 patients in New York City. PLoS ONE. 2021;16(7):e0255171.", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.eclinm.2021.101029", "author": "CH Lo", "doi-asserted-by": "publisher", "first-page": "101029", "journal-title": "EClinical Medicine.", "key": "373_CR38", "unstructured": "Lo CH, Nguyen LH, Drew DA, Warner ET, Joshi AD, Graham MS, Anyane-Yeboa A, Shebl FM, Astley CM, Figueiredo JC, Guo CG, Ma W, Mehta RS, Kwon S, Song M, Davies R, Capdevila J, Sudre CH, Wolf J, Cozier YC, Rosenberg L, Wilkens LR, Haiman CA, Marchand LL, Palmer JR, Spector TD, Ourselin S, Steves CJ, Chan AT, COPE Consortium. Race, ethnicity, community-level socioeconomic factors, and risk of COVID-19 in the United States and the United Kingdom. EClinical Medicine. 2021;38:101029.", "volume": "38", "year": "2021" } ], "reference-count": 38, "references-count": 38, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s40744-021-00373-1" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Immunology and Allergy", "Rheumatology" ], "subtitle": [], "title": "Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "8" }